This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
Patients with favourable clinical response at TOC (%)§
Baseline pathogens: predominantly K. pneumoniae and P. aeruginosa including some ceftazidime-resistant strains. 100 patients (28%) had > 1 ceftazidime-resistant isolate.
333 hospitalised adults with a cUTI or cIAI
1033 hospitalised adults with cUTI.
1066 hospitalised adults with cIAI
§Non-inferiority was concluded if the lower limit of the 95% CI was greater than –12.5%.2
†cMITT population comprised patients with minimum disease criteria but excluded patients with only non-target pathogens.2
‡The clinically evaluable population comprised patients in the cMITT population who received an adequate course of treatment and had an assessable clinical outcome within the assessment window, no protocol deviations that could affect the assessment of efficacy, and no unacceptable previous or concomitant antibiotics.2
*Consideration should be given to official guidance on the appropriate use of antibacterial agents
Abbreviations:
AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; HAP, hospital-acquired pneumonia; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; TOC, test of cure; VAP, ventilator-associated pneumonia; cIAI, complicated intra-abdominal infection; E.coli, Escherichia coli; MITT, modified intention-to-treat; cUTI, complicated urinary tract infection.
Prescribing information
Zavicefta® (ceftazidime and avibactam)
Great Britain
Zavicefta®(ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion
Northern Ireland
Zavicefta®(ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion
Meronem® (meropenem trihydrate)
Meronem® (meropenem triydrate) IV 1g
Meronem® (meropenem triydrate) IV 500mg
Tygacil® (tigecycline)
Great Britain
Tygacil® (tigecycline) 50mg powder for solution for infusion
Northern Ireland
Tygacil® (tigecycline) 50mg powder for solution for infusion
References:
Professor of Pulmonology and Respiratory Critical Care Medicine at University of Barcelona, Spain, talks about hospital-acquired pneumonia and ventilator-associated pneumonia, as well as the REPROVE study, a Phase III randomised clinical trial comparing ceftazidime-avibactam to meropenem.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021